| Transcriptional basis of mouse and human dendritic cell heterogeneity CC Brown, H Gudjonson, Y Pritykin, D Deep, VP Lavallée, A Mendoza, ... Cell 179 (4), 846-863. e24, 2019 | 412 | 2019 |
| Regenerative lineages and immune-mediated pruning in lung cancer metastasis AM Laughney, J Hu, NR Campbell, SF Bakhoum, M Setty, VP Lavallée, ... Nature medicine 26 (2), 259-269, 2020 | 308 | 2020 |
| Mubritinib targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia I Baccelli, Y Gareau, B Lehnertz, S Gingras, JF Spinella, S Corneau, ... Cancer cell 36 (1), 84-99. e8, 2019 | 195 | 2019 |
| GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo C Pabst, A Bergeron, VP Lavallée, J Yeh, P Gendron, GL Norddahl, ... Blood, The Journal of the American Society of Hematology 127 (16), 2018-2027, 2016 | 188 | 2016 |
| The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias VP Lavallée, I Baccelli, J Krosl, B Wilhelm, F Barabé, P Gendron, ... Nature genetics 47 (9), 1030-1037, 2015 | 161 | 2015 |
| Cohesin members Stag1 and Stag2 display distinct roles in chromatin accessibility and topological control of HSC self-renewal and differentiation AD Viny, RL Bowman, Y Liu, VP Lavallée, SE Eisman, W Xiao, ... Cell stem cell 25 (5), 682-696. e8, 2019 | 111 | 2019 |
| Expression of immunoproteasome genes is regulated by cell-intrinsic and–extrinsic factors in human cancers A Rouette, A Trofimov, D Haberl, G Boucher, VP Lavallée, G D’Angelo, ... Scientific reports 6 (1), 34019, 2016 | 103 | 2016 |
| Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia NA McNeer, J Philip, H Geiger, RE Ries, VP Lavallee, M Walsh, M Shah, ... Leukemia 33 (8), 1934-1943, 2019 | 87 | 2019 |
| Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors VP Lavallée, J Krosl, S Lemieux, G Boucher, P Gendron, C Pabst, I Boivin, ... Blood, The Journal of the American Society of Hematology 127 (24), 3054-3061, 2016 | 81 | 2016 |
| High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML L Simon, JF Spinella, CY Yao, VP Lavallée, I Boivin, G Boucher, ... Blood, The Journal of the American Society of Hematology 135 (21), 1882-1886, 2020 | 76 | 2020 |
| Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets A Maiga, S Lemieux, C Pabst, VP Lavallée, M Bouvier, G Sauvageau, ... Blood Cancer Journal 6 (6), e431-e431, 2016 | 75 | 2016 |
| EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations VP Lavallée, P Gendron, S Lemieux, G D’Angelo, J Hébert, G Sauvageau Blood, The Journal of the American Society of Hematology 125 (1), 140-143, 2015 | 73 | 2015 |
| H3 K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations B Lehnertz, YW Zhang, I Boivin, N Mayotte, E Tomellini, J Chagraoui, ... Blood, The Journal of the American Society of Hematology 130 (20), 2204-2214, 2017 | 72 | 2017 |
| RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature VP Lavallée, S Lemieux, G Boucher, P Gendron, I Boivin, RN Armstrong, ... Blood, The Journal of the American Society of Hematology 127 (20), 2498-2501, 2016 | 72 | 2016 |
| Genetic characterization of ABT-199 sensitivity in human AML R Bisaillon, C Moison, C Thiollier, J Krosl, ME Bordeleau, B Lehnertz, ... Leukemia 34 (1), 63-74, 2020 | 71 | 2020 |
| MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia FC Brown, E Still, RP Koche, CY Yim, S Takao, P Cifani, C Reed, ... Cancer discovery 8 (4), 478-497, 2018 | 62 | 2018 |
| Venous thromboembolism in brain tumors: risk factors, molecular mechanisms, and clinical challenges J Riedl, C Ay Seminars in thrombosis and hemostasis 45 (04), 334-341, 2019 | 57 | 2019 |
| Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML S Garg, A Reyes-Palomares, L He, A Bergeron, VP Lavallée, S Lemieux, ... Blood, The Journal of the American Society of Hematology 134 (3), 263-276, 2019 | 49 | 2019 |
| Chemogenomic Landscape of RUNX1-mutated AML Reveals Importance of RUNX1 Allele Dosage in Genetics and Glucocorticoid Sensitivity L Simon, VP Lavallée, ME Bordeleau, J Krosl, I Baccelli, G Boucher, ... Clinical cancer research 23 (22), 6969-6981, 2017 | 48 | 2017 |
| High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia M Marquis, C Beaubois, VP Lavallée, M Abrahamowicz, C Danieli, ... Blood cancer journal 8 (8), 68, 2018 | 45 | 2018 |
